Review article: Trials on reflux disease - The role of acid secretion and inhibition

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 5, 2004, Pages 2-8

  Sonnenberg, A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; EPIDEMIOLOGICAL DATA; ESOPHAGUS PH; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RISK FACTOR; RISK REDUCTION; STOMACH ACID; STOMACH ACID SECRETION; SYSTEMATIC REVIEW;

EID: 7044270609     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02131.x     Document Type: Conference Paper

References (41)

1. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
2. A Gallup Survey on Heartburn Across America. Washington DC: The Gallup Organization Inc. 1988.
3. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
4. Lundell LR, Dent J, Bennet JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation the Los Angeles classification. Gut 1999; 45: 172-80.
5. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-8.
6. Avidan B. Sonnenberg A, Schnell TG, Sontag SJ. There are no reliable symptoms for erosive esophagitis or Barrett's esophagus: endoscopic diagnosis still essential. Aliment Pharmacol Ther 2002; 16: 735-42.
7. Bate CM, Griffin SM; Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 547-55.
8. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
9. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group Eur J Gastroenterol Hepatol 1998; 10: 119-24.
10. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
11. Koelz HR, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198-205.
12. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999; 94: 92-7.
13. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 1992; 102: 109-18.
14. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
15. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001: 96: 656-65.
16. Chiba N, De Gara CJ, Wilkinson JM, Hunt JM. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
17. Vigneri S, Termini R. Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
18. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
19. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994; 107: 1312-8.
20. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992: 51 (Suppl; 51(Suppl. 1): 59-67.
21. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal oesophageal reflux disease. Gut 1992; 33: 118-24.
22. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal ocsophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
23. Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40(Suppl. 2): 24S-49S.
24. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57.
25. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux esophagitis. Gut 1999; 45: 181-5.
26. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's esophagus. Gut 1997; 40: 9-13.
27. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
28. Richter J. Do we know the cause of reflux disease? Eur J Gastroenterol Hepatol 1999; 11(Suppl. 1): S3-9.
29. Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA+ Helicobacter pylori in reflux oesophagitis. Gut 2001; 49: 341-6.
30. Chow WH. Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-90.
31. El-Omar EM, Oien K. El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
32. Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664-8.
33. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
34. Malaty HM, Evans DG, Evans DJ, Graham DY. Helicobacter pylori in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology 1992; 103: 813-6.
35. Sonnenberg A. Epidemiologie und Spontanverlauf der Refluxkrankheit. In: Blum AL, Siewert JR, eds. Refluxtherapie. Berlin: Springer-Verlag, 1981: 85-106.
36. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.
37. Hirschowitz BI. Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls. Dig Dis Sci 1996; 41: 2115-22.
38. Hirschowitz BI. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996; 41: 1384-91.
39. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
40. Vaezi MY. Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-9.
41. Avidan B. Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-6.